Study claims antidepressants benefit only small portion of patients

Share this article:

A new study of prescription antidepressants published this week suggests the drugs may be no more effective than placebo in treating the most common forms of depression.

“Although patients get better when they take antidepressants, they also get better when they take a placebo, and the difference in improvement is not very great,” said the study's lead researcher Irving Kirsch, a professor of psychology at the University of Hull in Great Britain, in a prepared statement. “This means that depressed people can improve without chemical treatments.”

Kirsch and colleagues collected data on 35 clinical trials of antidepressant selective serotonin reuptake inhibitors (SSRIs) submitted to the FDA. Drugs in the trials included fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone) and paroxetine (Paxil). 

According to Kirsch's analysis of the data, patients taking the antidepressant drugs fared no better than patients taking placebo. The result appeared to be the same in patients who were mildly or moderately depressed. The antidepressants appeared to benefit a small group of patients with severe depression, the study found.

The findings were published online Feb. 25 in the journal PLoS Medicine. For more, information click here.

Global sales of antidepressants were approximately $21 billion in 2007.

Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.